Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.23.2
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
6 Months Ended
Jun. 30, 2023
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Periods Ended June 30, 

Six-Month Periods Ended June 30, 

($ in thousands)

    

2023

    

2022

    

2023

    

2022

Qbrexza®

$

8,079

$

6,111

$

12,173

$

13,487

Accutane®

 

5,579

 

5,200

 

10,227

 

10,107

Amzeeq®

1,374

1,265

2,568

4,731

Zilxi®

572

555

886

1,297

Targadox®

664

2,756

1,457

5,390

Exelderm®

 

538

 

1,313

 

1,049

 

2,017

Ximino®

155

1,035

766

2,002

Total product revenues

$

16,961

$

18,235

$

29,126

$

39,031

Schedule of other revenue

    

Three-Month Periods Ended June 30,

    

Six-Month Periods Ended June 30,

($ in thousands)

    

2023

    

2022

    

2023

    

2022

Other revenue

 

$

211

 

$

56

$

259

 

$

2,556

Total other revenue

$

211

$

56

$

259

$

2,556